Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,884.82 +2,201.56 (+3.35%) CMC Crypto 200
1,376.61 +46.00 (+3.46%)
Cara Therapeutics, Inc. (CARA)
After hours:
| Previous close | 0.3651 |
| Open | 0.3712 |
| Bid | 0.3686 x 100 |
| Ask | 0.3742 x 200 |
| Day's range | 0.3660 - 0.3949 |
| 52-week range | 0.2400 - 3.4500 |
| Volume | |
| Avg. volume | 904,095 |
| Market cap | 20.361M |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2600 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.50 |
GlobeNewswireCara Therapeutics Announces Exploration of Strategic Alternatives
Piper Sandler & Co. to act as financial advisorSTAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that it has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives. “We are committed to evaluating a range of strategic options to maximize value for our shareholders,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “As part of this effo
- GlobeNewswire
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the
ZacksCara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of -47.37% and 5.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
